Moderna (MRNA) stock gains as company posts better than expected Q3 results driven by its updated COVID-19 vaccine. Read more ...

The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory syncytial virus vaccine raked in just $10 ...

With the possibility of RFK Jr. being involved in health policy in the next administration, vaccination, especially mRNA ...

The rapid development of mRNA vaccines during the COVID-19 pandemic exemplified the complex as well as vital role RNAs play ...

They found that mRNA vaccines that target C. diff cells and the toxins they produce generated a lasting immune response in mice and hamsters.

Moderna (MRNA) shares are getting a boost in Thursday's pre-market trading as the pharmaceutical giant reported an unexpected profit in its third quarter. The company posted $1.86 billion in revenue ...

This valuable study reveals extensive binding of eukaryotic translation initiation factor 3 (eIF3) to the 3' untranslated regions (UTRs) of efficiently translated mRNAs in human pluripotent stem ...

Reports third quarter revenues of $1.9 billion, GAAP net income of $13 million and GAAP EPS of $0.03 Achieves year-to-date ...

Moderna stock rises as Q3 revenue beats estimates at $1.83 billion, driven by strong U.S. COVID-19 vaccine sales. EPS of $0.03 exceeds expectations.

The Cambridge, Massachusetts-based company said it had profit of 3 cents per share. The results surpassed Wall Street expectations. The average estimate of 12 analysts surveyed by Zacks Investment ...

Thursday, November 6, 2024 The other long-expected big news item for market participants this week comes this afternoon, with the Federal Open Market Committee (FOMC) determining a new Fed funds rate.

Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its COVID-19 vaccine, even with low revenue from its new respiratory syncytial ...